NCT06621654View on ClinicalTrials.gov

Clinical Trial of Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

November 15, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions
Haemophilus Influenzae Type B Infection
Interventions
BIOLOGICAL

Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine

1 dose (0.5ml) of vaccine on day 0, Intramuscular injection

BIOLOGICAL

Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine

1 dose (0.5ml) of vaccine on day 0, Intramuscular injection

BIOLOGICAL

Haemophilus Influenzae Type b Conjugate Vaccine

1 dose (0.5ml) of vaccine on day 0, Intramuscular injection

BIOLOGICAL

Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine

3 doses (0.5ml per dose) at day 0, 1 month, and 18 months of age, Intramuscular injection

BIOLOGICAL

Haemophilus Influenzae Type b Conjugate Vaccine

3 doses (0.5ml per dose) at day 0, 1 month, and 18 months of age, Intramuscular injection

BIOLOGICAL

Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine

4 doses (0.5ml per dose) at day 0, 2, 4 month, and 18 months of age, Intramuscular injection

BIOLOGICAL

Haemophilus Influenzae Type b Conjugate Vaccine

4 doses (0.5ml per dose) at day 0, 2, 4 month, and 18 months of age. Intramuscular injection

Trial Locations (1)

Unknown

Jiulongpo District Center for Disease Control and Prevention, Chongqing

Sponsors
All Listed Sponsors
lead

CanSino Biologics Inc.

INDUSTRY

NCT06621654 - Clinical Trial of Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine | Biotech Hunter | Biotech Hunter